Skip to main content
. 2024 Mar 20;6(4):e238–e250. doi: 10.1016/S2589-7500(23)00267-4

Table 3.

Diagnostic test performance of PIERS-ML risk strata

PIERS-ML output (for outcomes within 2 days) Hypertensive pregnant women in stratum Hypertensive pregnant women with an outcome within 2 days Hypertensive pregnant women within risk stratum with an outcome within 7 days Hypertensive pregnant women within risk stratum with an outcome at any time
Primary combined adverse maternal outcome (AUROC 0·80 [0·76–0·84], AUPRC 0·38)
Very low risk ≤0·5% 8 (0·7%) 0 1 (12·5%) 1 (12·5%)
Low risk 0·6–3·0% 321 (29·1%) 7 (2·2%) 13 (4·0%) 21 (6·5%)
Moderate risk 3·1–18·6% 676 (61·3%) 36 (5·3%) 58 (8·6%) 76 (11·2%)
High risk 18·7–45·5% 87 (7·9%) 23 (26·4%) 25 (28·7%) 28 (32·2%)
Very high risk ≥45·6% 11 (1·0%) 10 (90·9%) 10 (90·9%) 10 (90·9%)
Excluding mean platelet volume (AUROC 0·80 [0·76–0·84], AUPRC 0·39)
Very low risk ≤0·5% 8 (0·7%) 0 1 (12·5%) 1 (12·5%)
Low risk 0·6–3·0% 340 (30·8%) 8 (2·4%) 14 (4·1%) 22 (6·5%)
Moderate risk 3·1–18·6% 656 (59·5%) 35 (5·3%) 56 (8·5%) 74 (11·3%)
High risk 18·7–45·5% 86 (7·8%) 22 (25·6%) 25 (29·1%) 28 (32·6%)
Very high risk ≥45·6% 13 (1·2%) 11 (84·6%) 11 (84·6%) 11 (84·6%)
Including fibrinogen and activated prothrombin time (AUROC 0·80 [0·76–0·84], AUPRC 0·38)
Very low risk ≤0·5% 7 (0·6%) 0 1 (14·3%) 1 (14·3%)
Low risk 0·6–3·0% 291 (26·4%) 6 (2·1%) 12 (4·1%) 20 (6·9%)
Moderate risk 3·1–18·6% 709 (64·3%) 39 (5·5%) 61 (8·6%) 79 (11·1%)
High risk 18·7–45·5% 82 (7·4%) 19 (23·2%) 21 (25·6%) 24 (29·3%)
Very high risk ≥45·6% 14 (1·3%) 12 (85·7%) 12 (85·7%) 12 (85·7%)
fullPIERS (AUROC 0·62 [0·56–0·68], AUPRC 0·33)
Very low risk ≤1·3% 6 (0·5) 2 (33·3%) 2 (33·3%) 2 (33·3%)
Low risk NA NA NA NA NA
Moderate risk 1·4–30·4% 1011 (91·5%) 51 (5·0%) 78 (7·7%) 105 (10·74)
High risk 30·5–70·6% 62 (5·6%) 11 (17·7%) 14 (22·6%) 14 (22·6%)
Very high risk ≥70·7% 26 (2·4%) 12 (46·2%) 13 (46·2%) 15 (57·7%)
fullPIERS using PIERS-ML thresholds (AUROC 0·62 [0·56–0·68], AUPRC 0·33)
Very low risk ≤0·5% 3 (0·3%) 0 0 0
Low risk 0·6–3·0% 31 (2·8%) 4 (12·9%) 5 (16·1%) 5 (16·1%)
Moderate risk 3·1–18·6% 868 (79·0%) 42 (4·8%) 66 (7·6%) 89 (10·3%)
High risk 18·7–45·5% 146 (13·3%) 12 (8·2%) 16 (11·0%) 19 (13·0%)
Very high risk ≥45·6% 51 (4·6%) 18 (35·3%) 20 (39·2%) 22 (43·1%)
fullPIERS refitted on combined dataset (AUROC 0·67 [0·62–0·72], AUPRC 0·25)
Very low risk ≤1·0% 1 (0·1%) 0 0 0
Low risk NA NA NA NA NA
Moderate risk 1·1–15·5% 1031 (93·3%) 60 (5·8%) 87 (8·4%) 115 (11·2%)
High risk 15·6–44·2% 64 (5·8%) 11 (17·2%) 15 (23·4%) 16 (25·0%)
Very high risk ≥44·3% 9 (0·8%) 5 (55·6%) 5 (55·6%) 5 (55·6%)
fullPIERS refitted on combined dataset using PIERS-ML thresholds (AUROC 0·67 [0·62–0·72], AUPRC 0·25)
Very low risk ≤0·5% 0 NA NA NA
Low risk 0·6–3·0% 108 (9·8%) 5 (4·6%) 6 (5·6%) 13 (12·0%)
Moderate risk 3·1–18·6% 943 (85·8%) 57 (6·0%) 85 (9·0%) 105 (11·1%)
High risk 18·7–45·5% 40 (3·6%) 9 (22·5%) 11 (27·5%) 12 (30·0%)
Very high risk ≥45·6% 8 (0·7%) 5 (62·5%) 5 (62·5%) 5 (62·5%)
External validation cohort (AUROC 0·76 [0·71–0·82], AUPRC 0·17)
Very low risk ≤0·5% 9 (0·3%) 0 0 0
Low risk 0·6–3·0% 1512 (52·1%) 17 (1·1) 22 (1·5) 34 (2·2)
Moderate risk 3·1–18·6% 1324 (45·7%) 47 (3·5) 55 (4·2) 65 (4·9)
High risk 18·7–45·5% 52 (1·8%) 17 (32·7) 20 (38·5) 20 (38·5)
Very high risk ≥45·6% 3 (0·1%) 2 (66·7) 2 (66·7) 2 (66·7)

Data are n (%). Risk strata determined by diagnostic test performances for first occurrence of any component of the primary combined adverse maternal outcome within 2 days: very low risk –LR <0·1; low risk –LR 0·1 to 0·2; moderate risk +LR <5·0 and –LR >0·2; high risk +LR 5·0 to 10·0; very high risk +LR >10·0. AUROC=area under the receiver-operator characteristic. AUPRC=area under the precision-recall curve. NA=could not select a probability threshold greater than the very low risk threshold that produced a negative likelihood ratio less than or equal to 0·2, when using predicted probabilities from the fullPIERS model.